Halpern v. Peritec Biosciences Ltd.

383 F. App'x 943
CourtCourt of Appeals for the Federal Circuit
DecidedJune 23, 2010
Docket2010-1042
StatusUnpublished
Cited by1 cases

This text of 383 F. App'x 943 (Halpern v. Peritec Biosciences Ltd.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Halpern v. Peritec Biosciences Ltd., 383 F. App'x 943 (Fed. Cir. 2010).

Opinion

BRYSON, Circuit Judge.

David Halpern filed a complaint in the United States District Court for the Northern District of Ohio in which he asserted ten claims against PeriTec Biosci-ences, Ltd., PeriTec Biosciences, Rajesh Khosla, and Timur Sarac (together “defendants”). The district court dismissed two of the claims under Fed.R.Civ.P. 12(b)(6), and exercised its discretion not to address the remaining claims under its supplemental jurisdiction. On appeal, Mr. Halpern challenges the judgment with respect to only one of the ten claims. For the reasons stated below, we affirm.

I

In his complaint, Mr. Halpern alleged that the defendants selected him to “assist in the design of a catheter delivery system for tissue-lined [vascular] stents.” As part of their employment offer, Mr. Halpern alleged, the defendants agreed to compensate him with a salary, bonuses, and “equity units” in PeriTec. However, despite what Mr. Halpern refers to as his subsequent “association” with PeriTec, he contends that the employment agreement formalizing the terms and conditions of his employment with PeriTec was “never fully executed.” The complaint further alleged that Mr. Khosla and Mr. Sarac filed patent applications for two devices that Mr. Hal-pern invented — a stent compressing device and a cartridge device for delivering stents within the vascular system. Those applications, according to Mr. Halpern, failed to correctly identify him as the sole inventor of the claimed devices.

*945 The second claim in Mr. Halpern’s complaint was entitled “Patent Rights” and was brought under the authority of the Patent Act, 35 U.S.C. §§ 1 et seq. In that claim, Mr. Halpern alleged that he had invented and reduced to practice the stent compressing device and the cartridge device, but that defendants Sarac and Khosla had filed patent applications for those devices in which they improperly named themselves as inventors and failed to name him as the sole inventor. As relief, Mr. Halpern sought an order enjoining the defendants “from ‘patent pending’ marketing, testing, and the exercise of provisional patent rights ... during the pendency of proceedings to correct inventorship on the patent applications.”

The defendants moved to dismiss all the claims of the complaint. With respect to the Patent Rights claim, the defendants moved to dismiss for failure to state a claim upon which relief could be granted. In their motion, they relied principally on a letter agreement dated March 24, 2005, to which Mr. Halpern had referred in his complaint. That letter stated that the employment agreement between PeriTee and Mr. Halpern was made contingent upon Mr. Halpern’s execution of certain other documents, which included a document entitled “Confidential Information and Invention Assignment Agreement.” Paragraph 5 of the Confidential Information and Invention Assignment Agreement provided as follows, in pertinent part:

Assignment of Inventions. Without further compensation, I hereby agree promptly to disclose to the Company and I hereby assign and agree to assign to the Company or its designee, my entire right, title, and interest in and to all Inventions which I may solely or jointly develop or reduce to practice during the period of my employment or consulting relationship with the Company which (a) pertain to any line of business activity of the Company, (b) are aided by the use of time, material or facilities of the Company, whether or not during normal working hours, or (c) relate to any of my work during the period of my employment or consulting relationship with the Company, whether or not during normal working hours. I acknowledge a permanent obligation promptly to execute assignments of Inventions covered by conditions (a), (b) or (c), herein, to the Company even after my relationship with the Company has been terminated.

That document bears Mr. Halpern’s signature and the date March 29, 2005. The defendants argued that by executing that document, Mr. Halpern prospectively and unequivocally surrendered his alleged patent rights at the outset of his employment with PeriTee. That assignment of rights was applicable to the two inventions at issue in this case, the defendants argued, because both inventions relate to the work that Mr. Halpern was hired to perform. Accordingly, the defendants argued that the Patent Rights claim should be dismissed.

The district court dismissed all of Mr. Halpern’s claims. The court dismissed the Patent Rights claim under Rule 12(b)(6), stating that Mr. Halpern “has absolutely no right[s] in the pending patent applications” because he had assigned those rights to PeriTee. The court added that “[ajssuming arguendo that the plaintiff does have rights in the applications, he should proceed through the U.S. Patent and Trademark Office for the relief he currently seeks from this Court.”

On appeal, Mr. Halpern does not challenge the district court’s order of dismissal with respect to any of the claims of the complaint except the Patent Rights claim. Moreover, even with respect to the Patent *946 Rights claim, Mr. Halpern now agrees that the claim should have been dismissed, but he argues that the dismissal should have been on a different ground. His appeal is directed solely at the court’s decision to dismiss that claim under Rule 12(b)(6) for failure to state a claim upon which relief could be granted. Even though he argued in the district court that the court had jurisdiction over the Patent Rights claim, Mr. Halpern has reversed field in this court and now contends that the district court should have dismissed that claim under Rule 12(b)(1) for want of jurisdiction. Mr. Halpern has made clear that he is seeking dismissal on jurisdictional grounds, rather than on the merits, because he wishes to avoid the possible collateral estoppel effects of the district court’s ruling that he validly assigned his potential inventorship rights when he executed the “Confidential Information and Invention Assignment Agreement” on March 29, 2005. A dismissal for lack of jurisdiction would not, of course, carry any such collateral estoppel consequences.

For the reasons set forth below, we do not agree with Mr. Halpern that the district court lacked jurisdiction to decide the Patent Rights claim. However, we conclude that the dismissal for failure to state a claim upon which relief can be granted should have been predicated solely on the fact that the patent applications in question had not issued as patents and that Mr. Halpern therefore did not have a cause of action in district court to contest the defendants’ representations as to inventor-ship.

II

Whether the district court possessed jurisdiction is a question of law that this court reviews de novo. See Pennington Seed, Inc. v. Produce Exch. No. 299, 457 F.3d 1334, 1338 (Fed.Cir.2006). When reviewing the application of the Federal Rules of Civil Procedure, we generally apply the law of the applicable regional circuit. Trilogy Commc’ns, Inc. v. Times Fiber Commc’ns, Inc.,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
383 F. App'x 943, Counsel Stack Legal Research, https://law.counselstack.com/opinion/halpern-v-peritec-biosciences-ltd-cafc-2010.